Centralization and Oncologic Outcomes in Ovarian Cancer

Summary

This is a multicenter, observational, retrospective and prospective study conducted within the REMO (Reggio Emilia - Modena) network in the Emilia-Romagna region (Italy), promoted by AUSL-IRCCS of Reggio Emilia. The study aims to evaluate the impact of surgical centralization and treatment strategies adopted during the COVID-19 pandemic on oncologic outcomes in patients diagnosed with the epithelial ovarian cancer (EOC) from 2018 to 2023. The retrospective component includes patients treated between 2018 and 2023, while the prospective component consists of clinical follow-up of those patients over the next five years.

Eligibility

Inclusion Criteria:

* Female patients aged between 18 and 99 years
* Histological and/or cytological diagnosis of epithelial ovarian cancer
* Patients evaluated by the Multidisciplinary Tumor Board (MTB) of the AUSL-IRCCS of Reggio Emilia
* Patients treated between January 1, 2018, and December 31, 2023
* Availability of clinical records and outcome data
* Signed informed consent where possible, in accordance with GDPR and Italian regulations

Exclusion Criteria:

* Patients without histological or cytological confirmation of epithelial ovarian cancer
* Incomplete or missing data for key clinical indicators
* Patients unable to provide informed consent and for whom recontact is not possible
* Patients deemed unable to understand and provide consent (e.g., severe cognitive impairment)

Conditions5

Browse More Trials